Emtricitabine (200mg) + Tenofovir Alafenamide (25mg) is a film-coated, blue, rectangle shaped tablet debossed with GSI on one side and 225 on the other side of the tablet.
Two antiretroviral agents form the combination. The two drug combination of Emtricitabine (FTC) and Tenofovir Alafenamide (TAF) is called Descovy both agents are HIV nucleoside analog reverse transcriptase inhibitors (NRTIs).
The dose of Descovy is fixed and
FTC is a synthetic nucleoside analog of cytidine which is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI)
TAF is a HIV NRTI, and an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5 – monophosphate.
It treats the human immune deficiency type 1 (HIV – 1) infection in adults and pediatric patients 12 years of age and older.
Descovy treats pre-exposure prophylaxis and reduces the risk of HIV in adults and adolescents.
It reduces the risk of spreading the HIV through sex.
Descovy does not cure HIV - 1 but it treats/prevents the individual from being affected by AIDS.
Make sure you are HIV – negative while taking the Descovy tablet.
Do not miss, discontinue the doses of the tablet or the treatment will not effective and delayed.
Do not overlap any two doses, maintain regular time intervals between any two doses of the treatment
Tell your doctor about your medical history, allergic reactions, and the list of tablet that you are already using.